2010 M&A Analytics: Some Observations

▤ Summary

Looks like some very interesting return-on-invested-capital multiples on the aggregate deal values: Marcardia, SmartCells, AkaRx, and Respivert all raised relatively little before being taken out for what could be very nice multiples. Several of these even had nice upfronts. As have many of the deals in 1Q 2011, as noted above.

▦ Linked Companies